New vaccine for renal cell carcinoma found to increase survival rates
July 30, 2012
by Bob Yirka
in Cancer
(Medical Xpress) -- Researchers working for German pharmaceutical company Immatics Biotechnologies GmbH, have outlined two successful outcomes for their multipeptide vaccine IMA901 in a paper theyve had published in the journal Nature Medicine. In it they describe how renal cell carcinoma (RCC) patients vaccinated with IMA901 experienced longer survival rates and how theyve also discovered key markers that they believe indicate which patients are most likely to benefit from the vaccine.
RCC, also known as hypernephroma, is the most common type of kidney cancer and survival rates for those who get it are low if the cancer metastases. Current treatment usually means removal of the cancerous tissue along with various forms of immunotherapy as radiation and chemotherapy are generally ineffective. Immunotherapy involves administering drugs that help the body identify cancerous cells as something that needs to be attacked and killed. To date, unfortunately, progress in this area of medicine has been slow, thus, the news that the vaccine developed my Immatics is showing some success is generating excitement in the cancer research world.
RCC vaccines are therapeutic, not preventative, hence they are only administered to people who have already been diagnosed. IMA901 was developed by noting the different antigens that come to exist on or around tumors as a result of the growth of cancerous cells under certain circumstances. The vaccine is made up of ten peptides that the research team has found cause stimulation of the immune system in patients that express the antigens theyve noted. That in turn causes the immune system to go on alert and to attack the tumors and hopefully kill them in the process.
IMA901 has currently gone through phase 1 and 2 clinical trials and is currently in phase 3. In the first two phases, the team found longer survival rates for the patients who volunteered to take part in the testing. Survival rates for those who undergo current treatment therapies are typically sixty to seventy percent for five years.
The team also detailed two serum biomarkers theyve discovered that they believe signal which RCC patients would be the most likely to benefit from IMA901, though they note that they wont know for sure how accurate they are until completion of phase 3 of their clinical trials.
More information: Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival, Nature Medicine (2012) doi:10.1038/nm.2883
Abstract
IMA901 is the first therapeutic vaccine for renal cell cancer (RCC) consisting of multiple tumor-associated peptides (TUMAPs) confirmed to be naturally presented in human cancer tissue. We treated a total of 96 human leukocyte antigen A (HLA-A)*02+ subjects with advanced RCC with IMA901 in two consecutive studies. In the phase 1 study, the T cell responses of the patients to multiple TUMAPs were associated with better disease control and lower numbers of prevaccine forkhead box P3 (FOXP3)+ regulatory T (Treg) cells. The randomized phase 2 trial showed that a single dose of cyclophosphamide reduced the number of Treg cells and confirmed that immune responses to multiple TUMAPs were associated with longer overall survival. Furthermore, among six predefined populations of myeloid-derived suppressor cells, two were prognostic for overall survival, and among over 300 serum biomarkers, we identified apolipoprotein A-I (APOA1) and chemokine (C-C motif) ligand 17 (CCL17) as being predictive for both immune response to IMA901 and overall survival. A randomized phase 3 study to determine the clinical benefit of treatment with IMA901 is ongoing.
Journal reference:
Nature Medicine
© 2012 Medical Xpress
-
Researchers find papillary renal cell carcinoma unresponsive to sunitinib
May 28, 2010 |
not rated yet |
0
-
Novel brain tumor vaccine acts like bloodhound to locate cancer cells
Jan 05, 2012 |
not rated yet |
0
-
Cuba releases world's first lung cancer vaccine
Sep 08, 2011 |
not rated yet |
0
-
Lymphocyte count indicates the prognosis of patients with renal cell carcinoma
Jun 01, 2011 |
not rated yet |
0
-
Cancer vaccine combination therapy shows survival benefit in breast cancer
May 15, 2012 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
-
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013
-
Alcohol and acetaminophen
May 13, 2013
-
Marie Curie's leukemia
May 13, 2013
- More from Physics Forums - Medical Sciences
More news stories
New smartphone application improves colonoscopy preparation
The use of a smartphone application significantly improves patients' preparation for a colonoscopy, according to new research presented today at Digestive Disease Week (DDW). The preparation process, which begins days in ...
Cancer
23 hours ago |
not rated yet |
0
Research examines new methods for managing digestive health
Research presented at Digestive Disease Week (DDW) explores new methods for managing digestive health through diet and lifestyle.
Cancer
May 19, 2013 |
not rated yet |
1
New colonoscope provides ground-breaking view of colon
A ground-breaking advance in colonoscopy technology signals the future of colorectal care, according to research presented today at Digestive Disease Week(DDW). Additional research focuses on optimizing the minimal withdrawal ...
Cancer
May 18, 2013 |
5 / 5 (2) |
0
ASCO: combo antibody therapy effective for melanoma
(HealthDay)—Concurrent use of two immune checkpoint antibodies—ipilimumab and nivolumab—may be effective for the treatment of advanced melanoma, according to a proof-of-principal study presented in ...
Cancer
May 17, 2013 |
not rated yet |
0
Risk factors ID'd for poor cutaneous cell CA outcomes
(HealthDay)—The risks of metastasis and death associated with cutaneous squamous cell carcinoma (CSCC) are low, but significant, and risk factors for poor outcome include tumor diameter, invasion beyond ...
Cancer
May 17, 2013 |
not rated yet |
0
|
New theory on genesis of osteoarthritis comes with successful therapy in mice
Scientists at Johns Hopkins have turned their view of osteoarthritis (OA) inside out. Literally. Instead of seeing the painful degenerative disease as a problem primarily of the cartilage that cushions joints, ...
Computational tool translates complex data into simplified 2-dimensional images
In their quest to learn more about the variability of cells between and within tissues, biomedical scientists have devised tools capable of simultaneously measuring dozens of characteristics of individual ...
Researchers identify a potential new risk for sleep apnea: Asthma
Researchers at the University of Wisconsin have identified a potential new risk factor for obstructive sleep apnea: asthma. Using data from the National Institutes of Health (Heart, Lung, and Blood Institute)-funded Wisconsin ...
Study finds that sleep apnea and Alzheimer's are linked
A new study looking at sleep-disordered breathing (SDB) and markers for Alzheimer's disease (AD) risk in cerebrospinal fluid (CSF) and neuroimaging adds to the growing body of research linking the two.
'Gap' for HIV vaccine efforts after latest setback
The hunt for an HIV vaccine has gobbled up $8 billion in the past decade, and the failure of the most recent efficacy trial has delivered yet another setback to 26 years of efforts.
Ginger compounds may be effective in treating asthma symptoms
Gourmands and foodies everywhere have long recognized ginger as a great way to add a little peppery zing to both sweet and savory dishes; now, a study from researchers at Columbia University shows purified components of the ...
Jul 31, 2012
Rank: not rated yet